as of —
₹—
Change
—
Day Open
₹—
Day High
₹—
Day Low
₹—
NSE Close — 19 Nov 2026
₹2,713.4
Change
+75.2 (2.85%)
Open
₹2,635.3
Prev. Close
₹2,638.2
Day High
₹2,719.9
Day Low
₹2,595.9
Volume Analysis
Traded
123,428
Delivered
67,726
Delivery %
54.87%
End-of-day NSE price via the official Bhavcopy — updated once daily after market close, not a live tick.
Strengths, Weaknesses, Opportunities & Threats
Strengths (2)
- •Strong return on equity (45.6%)
- •Strong operating margin (34.0%)
Weaknesses (0)
No signal for this stock
Opportunities (2)
- •Strong 3-year EPS growth (19.3%)
- •FII holding has been rising
Threats (0)
No signal for this stock
Rule-based signals from the fundamentals below — not investment advice.
Pivot Levels
| Type | R3 | R2 | R1 | Pivot | S1 | S2 | S3 |
|---|---|---|---|---|---|---|---|
| Classic | ₹2,880.9 | ₹2,800.4 | ₹2,756.9 | ₹2,676.4 | ₹2,632.9 | ₹2,552.4 | ₹2,508.9 |
| Fibonacci | ₹2,800.4 | ₹2,753.03 | ₹2,723.77 | ₹2,676.4 | ₹2,629.03 | ₹2,599.77 | ₹2,552.4 |
| Camarilla | ₹2,747.5 | ₹2,736.13 | ₹2,724.77 | ₹2,676.4 | ₹2,702.03 | ₹2,690.67 | ₹2,679.3 |
Support/resistance levels for today, calculated from the previous trading day's high/low/close.
Absolute Returns
YTD
+10.48%
1 Week
+2.18%
1 Month
+10.1%
3 Months
-6.51%
6 Months
+17.62%
1 Year
+8.15%
2Y/3Y/5Y not shown yet — price history tracking only goes back to mid-2025 so far.
Stock Vitals
Computed from the latest available annual financials.
Graham Number
₹265.01
Current price is above the Graham Number — Benjamin Graham's estimate of fair value based on earnings and book value.
DuPont ROE Breakdown
48.3%
Net margin 27.58% × asset turnover 0.83x × equity multiplier 2.11x
Company Overview
Sector
Healthcare
Market Cap
₹45,576 Cr
P/E (TTM)
40.2
ROE
45.6%
Book Value
₹111.0
Face Value
₹10.0
Source: Screener.in (Consolidated figures) — data as of 17 Nov 2026. Not investment advice.
TopFund Analysis
Glaxosmithkline Pharma Lt holds up reasonably well on TopFund's composite fundamentals check within the Healthcare sector, at 70/100. The strongest factor is Financial Strength (100/100), while Valuation (14/100) is the weakest area to weigh before deciding. Notably: Strong return on equity (45.6%); strong operating margin (34.0%). Strong 3-year EPS growth (19.3%).
TopFund Score — Fundamentals Quality
70/100 — GoodData confidence: 80/100 (High Confidence) — based on how complete and how fresh the underlying data is.
As of 19 Nov 2026 · How we calculate this →
Financial Strength
Growth
Valuation
Cash Flow
Corporate Governance
Momentum
Institutional Ownership
Business Quality
Risk & Volatility
Liquidity
From Screener.in
- +Company is almost debt free.
- +Company has a good return on equity (ROE) track record: 3 Years ROE 43.5%
- +Company has been maintaining a healthy dividend payout of 94.6%
- −Stock is trading at 24.1 times its book value
- −The company has delivered a poor sales growth of 5.49% over past five years.
Not investment advice — an automated read of public fundamentals data, for research context only.
Corporate Actions
Q2 FY27 earnings call: revenue up 21% to INR1,180 crore; EBITDA up 20%; Blenrep launch planned.
Video recording of analyst and institutional investor meetings uploaded on GSK investor website.
Recording of analyst and institutional investor meetings uploaded on GSK India investor website.
Source: BSE regulatory filings, via Screener.in.
Quarterly Results
Last several quarters
| Sep 2023 | Dec 2023 | Mar 2024 | Jun 2024 | Sep 2024 | Dec 2024 | Mar 2025 | Jun 2025 | Sep 2025 | Dec 2025 | Mar 2026 | Jun 2026 | Sep 2026 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Sales + | 957 | 805 | 930 | 815 | 1,011 | 949 | 974 | 805 | 980 | 1,041 | 995 | 938 | 1,184 |
| Expenses + | 668 | 587 | 673 | 584 | 689 | 658 | 641 | 554 | 644 | 670 | 644 | 643 | 782 |
| Operating Profit | 289 | 218 | 257 | 231 | 322 | 292 | 333 | 251 | 336 | 371 | 351 | 296 | 402 |
| OPM % | 30.0% | 27.0% | 28.0% | 28.0% | 32.0% | 31.0% | 34.0% | 31.0% | 34.0% | 36.0% | 35.0% | 31.0% | 34.0% |
| Other Income + | 28 | -135 | 32 | 36 | 39 | 35 | 41 | 44 | 36 | 50 | 36 | 44 | 73 |
| Interest | 0 | 0 | 1 | 0 | 0 | 0 | 1 | 0 | 1 | 1 | 1 | 1 | 0 |
| Depreciation | 18 | 17 | 18 | 16 | 17 | 19 | 15 | 16 | 17 | 20 | 13 | 16 | 15 |
| Profit before tax | 299 | 65 | 271 | 249 | 344 | 308 | 359 | 279 | 354 | 400 | 373 | 322 | 459 |
| Tax % | 27.0% | 30.0% | 28.0% | 27.0% | 27.0% | 25.0% | 27.0% | 27.0% | 27.0% | 26.0% | 26.0% | 26.0% | 27.0% |
| Net Profit + | 218 | 46 | 194 | 182 | 252 | 230 | 263 | 205 | 257 | 296 | 278 | 237 | 336 |
| EPS in Rs | 13 | 3 | 11 | 11 | 15 | 14 | 16 | 12 | 15 | 17 | 16 | 14 | 20 |
| Raw PDF | — | — | — | — | — | — | — | — | — | — | — | — | — |
| YoY Sales growth | 4 | 0 | 18 | 7 | 6 | 18 | 5 | -1 | -3 | 10 | 2 | 17 | 21 |
Source: Screener.in — figures in ₹ Crores unless marked %.
Profit & Loss (Yearly)
| Mar 2015 15m | Mar 2016 | Mar 2017 | Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | Mar 2026 | TTM | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Sales + | 3,305 | 2,838 | 2,908 | 2,871 | 3,128 | 3,224 | 2,926 | 3,278 | 3,252 | 3,454 | 3,749 | 3,822 | 4,159 |
| Expenses + | 2,672 | 2,360 | 2,489 | 2,363 | 2,527 | 2,567 | 2,327 | 2,516 | 2,447 | 2,545 | 2,570 | 2,512 | 2,739 |
| Operating Profit | 633 | 478 | 420 | 508 | 601 | 657 | 598 | 762 | 804 | 909 | 1,179 | 1,309 | 1,420 |
| OPM % | 19.0% | 17.0% | 14.0% | 18.0% | 19.0% | 20.0% | 20.0% | 23.0% | 25.0% | 26.0% | 31.0% | 34.0% | 34.0% |
| Other Income + | 149 | 125 | 119 | 70 | 131 | -262 | 9 | 1,401 | 103 | -21 | 149 | 166 | 203 |
| Interest | 0 | 0 | 0 | 0 | 1 | 6 | 4 | 2 | 2 | 2 | 1 | 3 | 3 |
| Depreciation | 25 | 25 | 27 | 38 | 49 | 83 | 79 | 68 | 66 | 70 | 67 | 66 | 64 |
| Profit before tax | 756 | 578 | 511 | 540 | 683 | 306 | 525 | 2,093 | 839 | 816 | 1,260 | 1,406 | 1,555 |
| Tax % | 37.0% | 35.0% | 34.0% | 35.0% | 35.0% | 70.0% | 32.0% | 19.0% | 27.0% | 28.0% | 26.0% | 26.0% | — |
| Net Profit + | 476 | 376 | 337 | 351 | 445 | 93 | 358 | 1,695 | 611 | 590 | 928 | 1,036 | 1,147 |
| EPS in Rs | 28 | 22 | 20 | 21 | 26 | 6 | 21 | 100 | 36 | 35 | 55 | 61 | 68 |
| Dividend Payout % | 111.0% | 113.0% | 75.0% | 85.0% | 76.0% | 727.0% | 142.0% | 90.0% | 89.0% | 92.0% | 99.0% | 93.0% | — |
| Sales growth | 29 | -14 | 2 | -1 | 9 | 3 | -9 | 12 | -1 | 6 | 9 | 2 | 12 |
Source: Screener.in — figures in ₹ Crores unless marked %.
Balance Sheet
| Mar 2015 | Mar 2016 | Mar 2017 | Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | Mar 2026 | Sep 2026 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Reserves | 1,744 | 2,099 | 1,922 | 1,973 | 1,970 | 1,651 | 1,309 | 2,494 | 1,572 | 1,608 | 1,782 | 2,098 | 1,712 |
| Borrowings + | 3 | 2 | 2 | 1 | 1 | 0 | 35 | 20 | 16 | 19 | 10 | 33 | 39 |
| Other Liabilities + | 1,384 | 869 | 995 | 1,889 | 1,771 | 1,315 | 1,602 | 1,950 | 1,570 | 1,760 | 2,147 | 2,023 | 2,048 |
| Total Liabilities | 3,216 | 3,055 | 3,004 | 3,947 | 3,911 | 3,136 | 3,115 | 4,633 | 3,327 | 3,557 | 4,108 | 4,324 | 3,969 |
| Fixed Assets + | 123 | 204 | 258 | 325 | 432 | 758 | 387 | 331 | 330 | 321 | 284 | 281 | 293 |
| CWIP | 115 | 268 | 605 | 923 | 1,003 | 120 | 13 | 30 | 20 | 14 | 14 | 33 | 35 |
| Investments | 0 | 6 | 0 | 0 | 0 | 0 | 0 | 366 | 518 | 813 | 1,118 | 1,392 | 1,525 |
| Other Assets + | 2,977 | 2,577 | 2,140 | 2,700 | 2,477 | 2,257 | 2,715 | 3,907 | 2,458 | 2,408 | 2,692 | 2,618 | 2,116 |
| Total Assets | 3,216 | 3,055 | 3,004 | 3,947 | 3,911 | 3,136 | 3,115 | 4,633 | 3,327 | 3,557 | 4,108 | 4,324 | 3,969 |
| Equity Capital | 85 | 85 | 85 | 85 | 169 | 169 | 169 | 169 | 169 | 169 | 169 | 169 | 169 |
Source: Screener.in — figures in ₹ Crores unless marked %.
Cash Flow
| Mar 2015 | Mar 2016 | Mar 2017 | Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | Mar 2026 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Cash from Operating Activity + | 338 | 139 | 234 | 473 | 409 | 490 | 578 | 811 | 484 | 582 | 1,290 | 903 |
| Cash from Investing Activity + | 180 | 499 | 301 | -104 | -153 | -57 | 418 | -406 | 808 | 9 | -46 | 397 |
| Cash from Financing Activity + | -497 | -638 | -511 | -307 | -358 | -428 | -696 | -524 | -1,543 | -562 | -769 | -737 |
| Net Cash Flow | 21 | 0 | 24 | 62 | -102 | 6 | 300 | -119 | -251 | 29 | 475 | 563 |
| Free Cash Flow | 175 | -69 | -24 | 639 | 166 | 336 | 536 | 2,371 | 451 | 573 | 1,273 | 870 |
| CFO/EBITDA Share of operating profit converting into cash: CFO (before tax) / Operating Profit | 93 | 72 | 94 | 133 | 101 | 103 | 121 | 122 | 93 | 92 | 116 | 93 |
Source: Screener.in — figures in ₹ Crores unless marked %.
Shareholding Pattern
Quarter-by-quarter — Promoters, FII, DII & public holding trend
| Dec 2023 | Mar 2024 | Jun 2024 | Sep 2024 | Dec 2024 | Mar 2025 | Jun 2025 | Sep 2025 | Dec 2025 | Mar 2026 | Jun 2026 | Sep 2026 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Public | 13.42% | 13.62% | 13.48% | 13.3% | 13.21% | 12.69% | 12.41% | 12.45% | 12.67% | 12.69% | 12.42% | 11.77% |
| Promoters | 75.0% | 75.0% | 75.0% | 75.0% | 75.0% | 75.0% | 75.0% | 75.0% | 75.0% | 75.0% | 75.0% | 75.0% |
| Government | 0.01% | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% |
| FII | 2.93% | 3.48% | 4.02% | 4.36% | 4.5% | 4.52% | 4.89% | 4.79% | 4.63% | 4.62% | 4.79% | 4.75% |
| DII | 8.64% | 7.9% | 7.51% | 7.34% | 7.3% | 7.79% | 7.71% | 7.75% | 7.7% | 7.68% | 7.81% | 8.47% |
Source: Screener.in — quarterly shareholding disclosures.
Peers Comparison
Healthcare — ranked by market cap
| Company | Market Cap (Cr) | P/E | P/B | ROE |
|---|---|---|---|---|
| Glaxosmithkline Pharma Lt (this stock) | 45,576 | 40.2 | 24.22 | 45.6% |
| Ipca Laboratories Ltd | 46,508 | 32.3 | 5.36 | 15.7% |
| Emcure Pharmaceuticals L | 44,370 | 39.9 | 8.29 | 20.1% |
| Ajanta Pharma Limited | 41,393 | 32.8 | 8.51 | 27.1% |
| Sai Life Sciences Limited | 41,003 | 107.0 | 15.19 | 15.4% |
| Anthem Biosciences Ltd | 51,355 | 81.4 | 15.65 | 22.3% |
| Global Health Limited | 38,864 | 60.0 | 8.97 | 15.2% |
Which Mutual Funds Hold Glaxosmithkline Pharma Lt?
Frequently Asked Questions about Glaxosmithkline Pharma Lt
Glaxosmithkline Pharma Lt (GLAXO) closed at ₹2,713.4 on NSE on 19 November 2026, up 75.2 (2.85%) from the previous close.
Glaxosmithkline Pharma Lt trades on the NSE (National Stock Exchange of India) under the symbol GLAXO.
Glaxosmithkline Pharma Lt has a trailing twelve-month P/E (price-to-earnings) ratio of 40.2.
Glaxosmithkline Pharma Lt has a dividend yield of 2.12%.
Glaxosmithkline Pharma Lt's 52-week high is ₹3,121.0 and its 52-week low is ₹2,088.0.
Glaxosmithkline Pharma Lt has a market capitalisation of ₹45,576 crore.
Glaxosmithkline Pharma Lt has a TopFund Quality Score of 70/100 (Good), a composite of profitability, balance-sheet health, growth and valuation. This is an analytical score based on public data, not personalized investment advice — see the full breakdown below before deciding.
Community Sentiment
What are other investors saying about Glaxosmithkline Pharma Lt?
No votes yet — be the first to share your view.
Sign in to voteDiscussion
User-generated content — not investment advice, and not verified or endorsed by TopFund.
Sign in to join the discussionNo comments yet — start the discussion.